Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United StatesIPO:
22 June 2018Website:
http://www.electrocore.comNext earnings report:
13 November 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 9 min agoDividend
Analysts recommendations
Institutional Ownership
ECOR Latest News
Ecora Resources PLC's (LSE:ECOR, TSX:ECOR, OTCQX:ECRAF) comments regarding the Voisey's Bay cobalt operation stream were the most significant component of its third quarter update, according to Peel Hunt. The four deliveries in the quarter matched the total deliveries for all of 2023, notes the broker.
Ecora Resources PLC (LSE:ECOR, TSX:ECOR, OTCQX:ECRAF) portfolio income dropped by 10% in its latest quarter as the contribution from its coking coal royalty at Kestrel fell sharply as expected. Without Kestrel, where mining shifted to areas outside of Ecora's royalty, income in the three months to end September 2024 rose by 4% to US$5 million helped by an almost tripled contribution from the cobalt operation at Voisey Bay.
electroCore (ECOR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Rockaway, New Jersey--(Newsfile Corp. - October 14, 2024) - electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate at the LD Micro Main Event XVII on Tuesday, October 29 at 4:30 p.m. PT at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.
Ecora Resources PLC (LSE:ECOR, TSX:ECOR, OTCQX:ECRAF) told investors it intends to move its shares from the ‘Transition' listing category on the London Stock Exchange, to the ‘Commercial Companies' category. These are among the new definitions under the newly reformed listing rules, brought in by the FCA this year.
Clinical trial demonstrates the ability of nVNS to accelerate sensorimotor learning in USAF Simulator Based Pilot Training Clinical trial demonstrates the ability of nVNS to accelerate sensorimotor learning in USAF Simulator Based Pilot Training
Ecora Resources PLC's (LSE:ECOR, TSX:ECOR, OTCQX:ECRAF) interim profits after tax at US$11.5 million were significantly higher than expectations, says broker Peel Hunt. A lower-than-expected impairment of the Kestrel coal royalty plus a positive revaluation of other royalty financial instruments helped the numbers with a net gain of $8.5m.
Ecora Resources PLC (LSE:ECOR, TSX:ECOR, OTCQX:ECRAF) saw a near US$28 million swing into the black in its latest half-year as the royalty specialist received a bumper contribution from its Kestrel asset in Australia. Profits jumped to US$17.9 million from a loss of US$10.2 million, as total income rose to US$51.3 million (from US$44.5 million) in the six months to end June 2024 with Kestrel contributing around 80% of royalties.
electroCore, Inc. (NASDAQ:ECOR ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Dan Goldberger - CEO Brian Posner - CFO Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Anthony Vendetti - Maxim Group Sean Lee - H.C. Wainwright Tyler Bussian - Brookline Capital Markets Walter Schenker - MAZ Partners Operator Greetings, and welcome to the electroCore Second Quarter 2024 Earnings Conference Call.
Seventh consecutive record quarterly net sales of $6.1 million, an increase of 73% over second quarter 2023 Company to host a conference call and webcast today, August 7, 2024 at 4:30 PM EST ROCKAWAY, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company and wellness company, today announced second quarter 2024 financial results.
- 1(current)
What type of business is electroCore?
electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
What sector is electroCore in?
electroCore is in the Healthcare sector
What industry is electroCore in?
electroCore is in the Medical Devices industry
What country is electroCore from?
electroCore is headquartered in United States
When did electroCore go public?
electroCore initial public offering (IPO) was on 22 June 2018
What is electroCore website?
https://www.electrocore.com
Is electroCore in the S&P 500?
No, electroCore is not included in the S&P 500 index
Is electroCore in the NASDAQ 100?
No, electroCore is not included in the NASDAQ 100 index
Is electroCore in the Dow Jones?
No, electroCore is not included in the Dow Jones index
When was electroCore the previous earnings report?
No data
When does electroCore earnings report?
The next expected earnings date for electroCore is 13 November 2024